• Bacterial infections

Zerbaxa Generic Name & Formulations

General Description

Ceftolozane, tazobactam; 1.5g/vial; pwd for IV infusion after reconstitution; preservative-free; contains sodium chloride 487mg/vial.

Pharmacological Class

Cephalosporin + beta-lactamase inhibitor.

How Supplied

Single-use vials—10


Generic Availability


Zerbaxa Indications


Susceptible complicated intra-abdominal infections (cIAI) in combination with metronidazole, complicated urinary tract infections (cUTI), including pyelonephritis, hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

Zerbaxa Dosage and Administration


Give by IV infusion over 1hr. ≥18yrs (CrCl >50mL/min): cIAI: 1.5g every 8hrs for 4–14 days (with IV metronidazole 500mg every 8hrs); cUTI: 1.5g every 8hrs for 7 days; HABP/VABP: 3g every 8hrs for 8–14 days. Renal impairment: cIAI, cUTI (CrCl 30–50mL/min): 750mg every 8hrs; (CrCl 15–29mL/min): 375mg every 8hrs; ESRD on hemodialysis: 750mg loading dose, followed by 150mg maintenance dose every 8hrs for remainder of treatment (give on dialysis days). HABP/VABP (CrCl 30–50mL/min): 1.5g every 8hrs; (CrCl 15–29mL/min): 750mg every 8hrs; ESRD on hemodialysis: 2.25g loading dose, followed by 450mg maintenance dose every 8hrs for remainder of treatment (give on dialysis days).


<18yrs: not established (HABP/VABP). Give by IV infusion over 1hr. Birth–<18yrs (eGFR >50mL/min/1.73m2): cIAI: 30mg/kg every 8hrs for 5–14 days (with metronidazole); cUTI: 30mg/kg every 8hrs for 7–14 days. For patients >50kg: do not exceed a max dose of 1.5g. Renal impairment (eGFR ≤50mL/min/1.73m2): not recommended.

Zerbaxa Contraindications


Cephalosporin, penicillin, or other beta-lactam allergy.

Zerbaxa Boxed Warnings

Not Applicable

Zerbaxa Warnings/Precautions


Discontinue if serious hypersensitivity reactions occur. Monitor CrCl at least daily in those with changing renal function and adjust dose. Renal impairment. Elderly. Pregnancy. Nursing mothers.

Zerbaxa Pharmacokinetics

See Literature

Zerbaxa Interactions

Not Applicable

Zerbaxa Adverse Reactions

Adverse Reactions

Nausea, diarrhea, headache, pyrexia, increased transaminases, renal impairment/failure; C. difficile-associated diarrhea, anaphylaxis; children: also thrombocytosis, leukopenia, abdominal pain, vomiting, anemia.

Zerbaxa Clinical Trials

See Literature

Zerbaxa Note

Not Applicable

Zerbaxa Patient Counseling

See Literature